Veterinary Pathology Online

http://vet.sagepub.com/ Feline Vaccine-associated Fibrosarcoma: Morphologic Distinctions

S. S. Couto, S. M. Griffey, P. C. Duarte and B. R. Madewell Vet Pathol 2002 39: 33 DOI: 10.1354/vp.39-1-33 The online version of this article can be found at: http://vet.sagepub.com/content/39/1/33

Published by:
http://www.sagepublications.com

On behalf of:
American College of Veterinary Pathologists, European College of Veterinary Pathologists, & the Japanese College of Veterinary Pathologists.

Additional services and information for Veterinary Pathology Online can be found at: Email Alerts: http://vet.sagepub.com/cgi/alerts Subscriptions: http://vet.sagepub.com/subscriptions Reprints: http://www.sagepub.com/journalsReprints.nav Permissions: http://www.sagepub.com/journalsPermissions.nav

>> Version of Record - Jan 1, 2002 What is This?

Downloaded from vet.sagepub.com by guest on August 12, 2013

Vet Pathol 39:3341 (2002)

Feline Vaccine-associated Fibrosarcoma: Morphologic Distinctions

S. S. COUTO, S. M. GRIFFEY, P. C. DUARTE,
AND

B. R. MADEWELL

Veterinary Medical Teaching Hospital (SSC), and Departments of Pathology, Microbiology and Immunology (SMG), Medicine and Epidemiology (PCD), and Surgical and Radiological Sciences (BRM), University of California, School of Veterinary Medicine, Davis, CA Abstract. Forty-four primary feline vaccine-associated brosarcomas and 16 recurrences were examined histologically for detailed morphologic characterization with emphasis on tumor grade, presence of neoplastic multinucleated giant cells, presence and proportion of T and B lymphocytes within the tumor, and thin and intermediate lament contents of neoplastic and stromal cells. The microvascularity and proliferation rates of central and peripheral areas of the tumors were also quantied by computerized image analysis. For primary brosarcomas, 11 of 44 (25%) were grade I, 21 of 44 (47.7%) were grade II, and 12 of 44 (27.3%) were grade III. The recurrences followed a similar pattern: 4 of 16 (25%) were grade I, 8 of 16 (50%) were grade II, and 4 of 16 (25%) were grade III. A positive correlation was found between the presence of neoplastic multinucleated giant cells and tumor grade. These cells were present in 9 of 12 (75%) of grade III and none of the grade I tumors. Prominent peritumoral lymphoid aggregates or follicles were present in 59% of the tumors, and many contained high proportions of T lymphocytes, varying from 19 to 87%. All brosarcomas were immunoreactive for vimentin and 28 of 44 (64%) were reactive for -smooth muscle actin. The actin-positive cells were either part of the tumor or formed a capsule around tumor nodules. The peripheral vascularity was signicantly higher than the central vascular density but no difference was found in tumor cell proliferation rates between the two areas. Centrally located, uid-lled micro- or macrocavitations were frequently observed in the large vaccine sarcomas and probably formed secondary to rapid tumor growth and central necrosis. Key words: Feline vaccine-associated sarcomas; inammation; microvascularity; multinucleated giant cells; myobroblasts; proliferation; tumor grade.

A unique tumor of cats was described by Hendrick and Goldschmidt in 1991.10 The appearance of feline vaccine-associated sarcomas coincided with increased rabies vaccination frequency and introduction of its subcutaneous route of administration. Aluminum vaccine adjuvants, common in killed virus vaccines, were suggested to play a role in the etiopathogenesis of these sarcomas.11 An epidemiologic study published in 1993 revealed a causal relationship between feline leukemia virus and rabies virus vaccinations and sarcoma development. In that study, risk for sarcomas after vaccination was associated with both adjuvanted (with or without aluminum) and nonadjuvanted vaccines.17 Most vaccine-associated sarcomas are categorized as brosarcomas but other histologic variants include rhabdomyosarcoma, myxosarcoma, chondrosarcoma, undifferentiated sarcoma, and malignant brous histiocytoma.5,9,19,20 Many of these sarcomas are associated with inammation. The inammatory reaction is characterized by follicular aggregates of lymphocytes and smaller numbers of plasma cells that are usually located perivascularly at the tumor periphery.5 Large round macrophages with blue-gray cytoplasm, presum33

ably associated with phagocytosed adjuvant material, are commonly found within, around, or adjacent to these sarcomas.9,1113,28 Tumors are often contiguous with granulation tissue that surrounds areas of necrosis at the vaccine site. Because of these histologic ndings, chronic or exacerbated inammation in response to adjuvants or other vaccine components has been implicated in the pathogenesis of the vaccine-associated sarcomas.5,11,12,20 Various histologic features of soft-tissue sarcomas have undergone scrutiny in both human and veterinary medicine. These include histologic grade, the presence of intratumoral neoplastic giant cells, intratumoral microvessel density, tumor proliferation index, and the presence of myobroblasts. These morphologic attributes were examined in a subset of feline vaccineassociated sarcomas in the present study in an effort to separate tumors into categories that might offer clues to tumor biology, or be tested as prognostic criteria for cats with sarcomas with or without treatment. The peritumoral lymphocytic inltrates were also phenotyped to provide additional information that might be useful when considering future immune therapy protocols.

Downloaded from vet.sagepub.com by guest on August 12, 2013

34

Couto, Griffey, Duarte, and Madewell

Vet Pathol 39:1, 2002

Materials and Methods

Morphology Parafn blocks containing brosarcomas collected from cats between 1991 and 1999 were retrieved from the pathology service of the Veterinary Medical Teaching Hospital at the University of California, Davis. Sarcomas arising in cats with appropriate vaccination histories at subcutaneous sites commonly used for vaccination (interscapular, lateral cervical, and thoracic regions, and caudal aspect of the thighs) with characteristic inammatory responses were included within the category of presumed vaccine-associated sarcomas. A total of 44 primary tumors (rst occurrences) and 16 recurrences were examined. Ten brosarcomas arising at unrelated sites (nonvaccination sarcomas) were examined similarly for comparison. For each specimen, 5-m, hematoxylin and eosinstained sections were made and examined microscopically. Tumors were graded using a scheme previously adapted to the dog based on cellular differentiation, presence and extension of necrosis within the neoplasm, and mitotic rate.25 All sarcomas were scored 13 for overall differentiation (1 tumor cells closely resembled the mature differentiated type; 2 tumors that had a dened histologic phenotype; and 3 poorly differentiated tumors), mitotic rates (1 19 mitotic gures per ten 400 elds; 2 1019 gures per ten 400 elds; and 3 20 or more gure per ten 400 elds), and necrosis (1 no necrosis; 2 necrosis of 50% of the total area of the specimen; and 3 necrosis of 50% of the total area). Final scores of 3 or 4 were designated grade I; scores of 5 or 6 were designated grade II; and scores of 7, 8, or 9 were designated grade III. When present, multinucleated giant cells were classied as of neoplastic, reactive, or of undetermined origin, according to previously described criteria.15,27 Briey, multinucleated giant cells within tumors were considered to be neoplastic based on immunoreactivity for proliferation marker Ki-67 and lack of reactivity for macrophage marker CD18. When present, the inammatory inltrate within and surrounding the tumors was examined and characterized as to its intensity, distribution, and cell types. Inammatory cells were identied as lymphocytes, plasma cells, macrophages, and neutrophils. To determine the intensity of inammation, we focused on the peritumoral lymphoid aggregates. The specimens were examined and scored subjectively based on the presence of lymphoid cells within all peritumoral elds in low magnication (40). When lymphoid aggregates or follicles were seen in all elds surrounding the tumor, the inltrate was considered to be abundant (score 3). When lymphoid cells, diffusely distributed or forming smaller follicles, were present in less than 50% of the peritumoral elds, the inltrate was considered to be moderate (score 2). When a careful search was required to determine the presence of small numbers of lymphoid cells with minimal or no follicular formation, the inltrate was considered to be mild (score 1). When no inammation was seen, the tumor was given a score of 0. Immunohistochemistry Immunohistochemistry was used to examine tumor-associated inammatory inltrates, tumor cellular proliferation,

intratumoral vessel density, and tumor cytoskeletal laments in primary brosarcomas. Ten nonvaccine sarcomas were examined only for thin and intermediate lament content (desmin, -smooth muscle actin [-SMA], and vimentin). Leukocyte subpopulations Twenty vaccine-associated sarcomas that contained a prominent inammatory reaction (inammation score 3) were selected from the 44 primary tumors. Tumors selected consisted of appropriate-sized biopsy specimens from cats with spindle cell sarcomas morphologically consistent with brosarcomas, preceding any form of treatment. Needle or punch biopsy specimens were omitted from examination. For each tumor, 5-m sections were immunostained to allow localization and differentiation between T lymphocytes, B lymphocytes, and macrophages. Tissue sections were immunostained using primary antibody, biotinylated secondary antibody, streptavidinperoxidase as third reagent, 3-amino9-ethycarbazol as chromagen, and hematoxylin as counterstain. Monoclonal antibodies were anti-CD3 for T lymphocytes (clone CD312, Vector Laboratories, Burlingame, CA), anti-CD79a (clone HM57, Dako Corp., Carpinteria, CA) for B lymphocytes, and anti-CD18 (clone Fe3.9F2, courtesy of P. F. Moore, University of California, Davis) for histiocytic cells. Three lymphoid aggregates or follicles per specimen were randomly selected for quantication of B and T lymphocytes. Sections stained for CD3 were selected for image analysis because of the clarity and specicity of staining. Immunostains for CD79a included nonspecic (background) stain and, therefore, were considered to be inappropriate for computer imaging. The CD79a-stained sections were used as reference for identifying unstained cells within the lymphoid follicles marked for CD3. Computerized image analysis Entire lymphoid follicles immunostained for CD3 were digitally captured (100) in tagged image le format with no compression (748 580 pixels) using a digital camera (ProgRes 3008, Kontron Elektronik, Mu nchen, Germany) mounted on a microscope (Zeiss Axioskop, Carl Zeiss Inc., Thornwood, NY) and connected to a computer. The images were analyzed on a Power Macintosh 8500/120-mhz computer using Photoshop 4.0 and NIH Image 1.61 (National Institutes of Health, Bethesda, MD) to quantitate the proportion of T cells per follicle. Such calculation was based on area with positive staining for CD3 with a color lter that selected areas with immunoreactivity (red) using Lab color mode (L luminance; a color components green to red; b color components blue to yellow). The entire follicle was selected and copied to a white background to be used as a base image from which quantication of T lymphocytes was done. Areas of immunoreactivity (T cells) within the follicle were selected using the lter, converted to black pixels, and copied to a white background (image A). The same procedure was used to determine areas representing nonT lymphocytes (image B) with a lter that selected light blue (hematoxylin-counterstained cells), assumed to be mostly B lymphocytes based on the correlation of the CD79a-stained sections. NIH Image 1.61 software was used to count the black and white pixels within each

Downloaded from vet.sagepub.com by guest on August 12, 2013

Vet Pathol 39:1, 2002

Morphology of Feline Vaccine-associated Sarcomas

35

image. The proportion of black pixels in image A represented total T cells (based on relative area), and the proportion of black pixels in image B represented the area of the follicle occupied by nonT (mostly B) lymphocytes. The blue lter was preferred over a total follicular area to exclude the white spaces (i.e., acellular areas and vascular lumens) and minimize the error caused by variation in cellular density among the follicles. The percentage of T cells per follicle was determined to be the area of black pixels in images A, divided by the sum of the area of black pixels in image A and B (T cells/total number of cells). The total estimated proportion of T lymphocytes per sarcoma was dened as the average area occupied by T cells among the three follicles counted per tumor. Tumoral vessel density Tissue sections of sarcomas were examined for tumoral vessel density both along the periphery of the tumor (growth fronts or hot spots) and within the central areas of the mass.1,33 Ten randomly selected elds of each region (center and periphery) of 20 primary tumors were evaluated. Vascular endothelium was identied with an immunolabel for factor VIIIrelated antigen in 10 randomly selected elds within both regions of each tumor. Tissues sections were stained using polyclonal rabbit anti-human factor VIIIrelated antigen (FVIII-rag, DAKO Corp., Santa Barbara, CA) as the primary antibody, followed by biotinylated, anti-rabbit secondary antibody, and alkaline phosphataselabeled streptavidin as a third reagent (StrAviGen Super Sensitive Kit, BioGenex, San Ramon, CA). The reaction was developed with a red chromagen (Fast Red, BioGenex) and counterstained with hematoxylin. Quantitation of tumoral vessels was done by digital imaging with methods similar to those described above but specically adapted for factor VIII-rag in canine tissues.7 Total tumor vessel density was calculated to be the average of the immunostained endothelium from three images analyzed (200) from each specimen or tumor. Cell proliferation index Proliferative fractions of 20 primary vaccine sarcomas were determined by means of immunohistochemistry for Ki67 antigen. Ki-67 was detected on 5m-thick tissue sections with a primary antibody, biotinylated alkaline phosphataselabeled streptavidin as secondary reagent, red chromagen (Fast Red, BioGenex), and hematoxylin counterstain. The primary antibody was murine anti-human Ki-67 (MIB-1, Oncogene Science Inc., Cambridge, MA). Positive and negative controls consisted of normal feline small intestines; intestinal crypts are considered sites of proliferation. The number of proliferating cells (positive cells for MIB-1 antibody) was manually counted with the assistance of computer imaging. Images of six nonoverlapping, 400 magnication elds along the periphery (growth fronts or hot spots) of the tumor were captured as previously described for leukocyte counts. Positive and negative nuclei were counted manually with the NIH 1.61 image analysis program, and the total numbers of labeled (red) and unlabeled (blue) cells were stored on a database. The number of elds was calculated so that a minimum of 1,000 cells was counted per specimen. The total number of cells counted per eld

varied depending on the cellular density of each tumor. Values obtained for positive and negative cells were summed and the proliferative fraction of peripheral regions of each tumor was determined to be the number of cells immunolabeled with MIB-1 (red) divided by the total number of cells counted per tumor. For comparison, the same procedure was applied to six nonoverlapping, 400 elds within the central region of each tumor. Cytoskeletal laments Immunohistochemistry was used to identify thin and intermediate laments including -SMA, desmin, and vimentin in 44 primary brosarcomas. Tissue sections were stained with primary antibody, biotinylated secondary antibody, streptavidinperoxidase as third reagent, 3-amino-9-ethycarbazol as chromagen, and hematoxylin as counterstain. Monoclonal antibodies were used to identify -SMA (BioGenex), vimentin (Dako Corp., Carpinteria, CA), and desmin (BioGenex). Specimens were scored as positive or negative for vimentin and desmin, whereas specimens stained for -SMA were scored on the basis of proportion of positive cells within the sarcoma: score 0 no immunolabeled tumor cells; 1 less than 50% of tumor cells immunolabeled; 2 approximately 50% of tumor cells immunolabeled; and 3 majority of tumor cells immunolabeled. Statistical analysis A computer program was used for all analyses (SPSS 9.0 for Windows, Microsoft, Redmond, WA). The chi-square test was used to assess associations between tumor grade and presence of -SMA, degree of inammation, and presence of giant cells. Fishers exact test was used to assess the association between -SMA and degree of inammation among all 44 tumors. Comparisons between tumor categories with respect to age, average vascularization, and central and peripheral proliferation rates were performed using the Kruskal-Wallis nonparametric analysis of variance. Spermans correlation was used to assess correlation between proliferation within the periphery and central regions of the tumor, and between peripheral and central vascularity. A Wilcoxon signed rank test was used to assess the differences in the mean peripheral and central proliferation rates. A level of signicance of 0.05 (P 0.05) was used for all tests.

Results The average age for cats at the time of rst tumor diagnosis was 10.3 years (median 9.5; range 314 years). The 44 cats with rst occurrence sarcomas included 21 females (47.7%) and 23 males (52.3%). Fibrosarcoma was the most frequent histologic variant; however, marked cellular pleomorphism occurred within an individual mass and among different tumors. Forty-four primary brosarcomas, 16 recurrent tumors, and 10 nonvaccine sarcomas were evaluated microscopically for determination of histologic grade, presence of giant cells, intensity and type of inammation,

Downloaded from vet.sagepub.com by guest on August 12, 2013

36

Couto, Griffey, Duarte, and Madewell

Vet Pathol 39:1, 2002

Fig. 1. Vaccine-associated sarcoma; cat. High-grade brosarcoma with numerous neoplastic multinucleated giant cells and a small focus of lymphocytic inammation (bottom left). HE. Bar 72 m. Fig. 2. Vaccine-associated sarcoma; cat. Large aggregates of blue-gray macrophages containing presumed vaccine adjuvant material (arrow) are interspersed with lymphocytes along the periphery of a tumor nodule (upper right). HE. Bar 104 m.

and presence of foreign material within macrophages (putative adjuvant). For primary brosarcomas, 11 of 44 (25%) were grade 1, 21 of 44 (47.7%) were grade II, and 12 of 44 (27.3%) were grade III. The histologic grade distribution was similar for 16 recurrent tumors: 4 (25%) were grade I, 8 (50%) were grade II, and 4 (25%) were grade III. Neoplastic multinucleated giant cells were present in 22 of 44 (50%) primary tumors and in 6 of 16 (37.5%) recurrent tumors (Fig. 1). Putative adjuvant material was seen in 10 of 44 (22.7%) primary tumors (22.7%), and 4 of 16 (25%) recurrent tumors. Six of 10 (60%) nonvaccine sarcomas were grade I, 2 of 10 (20%) were grade II, and 2 of 10 (20%) were grade III. In the vaccine-associated sarcomas examined here-

Fig. 3. Vaccine-associated sarcoma; cat. Central area of necrosis and cavitation within a large tumor. Note smaller, well-dened cavities. Surgical specimen. Bar 2 cm.

in, neutrophils were usually present within areas of necrosis, and small numbers of macrophages were admixed with lymphoplasmacytic in ltrates. Large, round macrophages containing blue-gray material (presumed adjuvant) within their cytoplasm were seen in 10 out of 44 (22.7%) primary tumors and in 4 out of 16 (25%) of recurrent tumors. The blue-gray macrophages formed clusters that were either entrapped within the periphery of the neoplasm or were distant from the tumor mass (Fig. 2). All sarcomas (primary and recurrent tumors) contained prominent lymphocytic inammation. Prominent or abundant inammation was seen in 59.1% of the primary tumors and 56.3% of recurrent tumors. Neoplastic multinucleated giant cells were present in 9 out of 12 (75%) grade III sarcomas, and in 13 of 21 (61.9%) grade II sarcomas, but none were seen in grade I sarcomas. A positive correlation was found between the presence of multinucleated giant cells and histologic grade. The proportion of giant cells increased as histologic grade progressed from 1 to 3 (P 0.001). No association was found between the presence or intensity of inammation and histologic grade (P 0.305). None of the nonvaccine sarcomas had associated lymphofollicular inammation, multinucleated giant cells, or blue-gray macrophages. A frequent macroscopic and occasionally microscopic nding among the feline vaccine-associated sarcomas was the presence of cavitations within central areas of tumors. Extensive, clear, uid-lled cavities, often clinically detected as a uctuating area similar to a seroma, were found in the larger tumor masses (Fig. 3). Histologically, the larger cavities were surrounded by a rim of necrotic tissue. Smaller micro-

Downloaded from vet.sagepub.com by guest on August 12, 2013

Vet Pathol 39:1, 2002

Morphology of Feline Vaccine-associated Sarcomas

37

scopic cavities were lined by viable tumor cells that resembled reactive granulation tissue. The proportion of T lymphocytes was quantied in 20 primary sarcomas that had a prominent inammatory inltrate (inammation score 3). Marked variation occurred in the T lymphocyte content between lymphoid follicles within the same tumor and among different tumors; the average T cell proportion of individual tumors ranged from as low as 19.3% to as high as 87.7%. The average T cell proportion within lymphoid follicles of all tumors was 46.9% with a standard deviation of 18.8%. No signicant difference was found in the average proportion of T cells among tumors of the three different histologic grades (P 0.8630). All 44 brosarcomas were strongly positive for vimentin and negative for desmin intermediate laments. Twenty-eight of 44 (64%) tumors were immunoreactive for -SMA but the immunolabel was heterogenous in intensity and distribution throughout the tumors. Of 28 actin-positive tumors, 28.6% had abundant immunolabeled cells (score 3), 32.1% had approximately 50% immunolabeled cells (score 2), and 39.3% had few immunolabeled cells (score 1). Immunoreactive cells were usually plump, polygonal or elongated, and contained abundant pink cytoplasm and large, often lobular nuclei. Tumor cells that were nonreactive for actin were generally smaller elongated spindle cells containing scant cytoplasm and fusiform nucleia more typical broblastic morphology. Multinucleated giant cells were either positive or negative for actin in different tumors. No signicant associations were found between tumor histologic grade and -SMA expression (P 0.173), or -SMA immunoreactivity and degree of inammation (P 0.508). Two of 10 nonvaccine-associated sarcomas showed weak reactivity for -SMA, one located on the pinna and another from the mammary gland. Tumoral vascular density at the periphery or growth fronts of the tumor was examined in 44 primary sarcomas of different histologic grades. The average tumoral vascular density varied from 0.30% to 4.84% among the different tumors. The average vascular density was 1.152% for grade I tumors, 1.766% for grade II tumors, and 1.556% for grade III tumors. No signicant associations were found between tumoral vascularity and histologic grade. The tumoral vascular densities and cell proliferation indexes of central (presumably quiescent) and peripheral areas (growth fronts) of 20 randomly selected primary tumors were compared. The average tumoral vascular density of the central areas from all tumors was 0.36% and the average proliferation index for the same region was 19.53%. The average vascular density from the pe-

riphery of all tumors (1.67%) was signicantly higher than the central vascular density (P 0.001). No signicant difference was found between the proliferation index of the periphery (22.15%) and central areas of the tumors (P 0.086). No signicant differences were found among the average peripheral proliferation rates (P 0.703) or vascular densities (P 0.512) among tumors of different histologic grades. Discussion Feline vaccine-associated brosarcomas were examined for morphologic distinctions. A grading scheme for soft-tissue sarcomas from human medicine that has been previously used to categorize canine softtissue sarcomas allowed separation of feline brosarcomas into three groups based on light microscopic attributescellular differentiation, presence or absence of necrosis, and mitotic rate.2,3,25 Histologic grading is currently the most important prognostic factor for human adult soft-tissue sarcomas with regard to probability for distant metastasis and overall survival rate.16,22,34 Whether this grading scheme has prognostic merit for the cat awaits clinical trial. Although the majority of cats from which tumors were derived in this study received treatment, inconsistencies with regard to tumor sizes, surgical methods, and postsurgery chemotherapy or radiotherapy preclude comparisons of tumor-free intervals and survival times between histologic grades. In cases in which more than one tumor from the same animal was available, the histologic grade of the recurrent tumor remained the same as that of the primary tumor (three out of seven), was lower than that of the primary tumor (two out of seven), or was higher than that of the primary tumor (two out of seven). Although these observations are limited, recurrent tumors do not seem to assume a more anaplastic phenotype when compared to the original (primary) tumor. Multinucleated giant cells are a common nding in feline vaccine-associated brosarcoma. 5 Analyses of the data suggested that the presence of intratumoral neoplastic giant cells may indicate a more poorly differentiated phenotype. In human patients with soft-tissue sarcomas, the presence of intratumoral neoplastic giant cells correlates with an aggressive, invasive tumor phenotype and is used as part of the paradigm to estimate prognosis.15,27 Because immunotherapy or biological methods of therapy might be used as adjuvants after surgical treatment of feline vaccine-associated sarcomas, objective methods for quantifying immune responses are required. Image analysis was used to quantitate B and T lymphocytes associated with peritumoral lymphoid follicles. Although considerable differences were found in lymphoid cell distribution among the bro-

Downloaded from vet.sagepub.com by guest on August 12, 2013

38

Couto, Griffey, Duarte, and Madewell

Vet Pathol 39:1, 2002

Fig. 4. Vaccine-associated sarcoma; cat. High proportion of T lymphocytes (arrow) within a lymphofollicular aggregate along the tumor nodule (T). Scattered T lymphocytes occur throughout the mass. CD3, avidinbiotinperoxidase complex method, Mayers hematoxylin counterstain. Bar 144 m.

sarcomas studied, a high proportion of T lymphocytes occurred within tumor-associated lymphoid follicles in many specimens, in spite of the fact that follicular formations are primary B cell areas of lymphoid structures (Fig. 4).4,32 The role of the lymphocyte in tumorigenesis or host response to feline vaccine-associated sarcomas is unknown. Myobroblasts, or cells with myobroblast features (myobroblast-like), have been described previously in feline vaccine-associated sarcomas based both on immunohistochemical and ultrastructural observa-

tions.21 Myobroblasts are mesenchymal spindle cells that have broblastic phenotype and produce collagen, but are distinguished by their capacity for contraction, the presence of cytoplasmic -SMA, and the presence of subplasmalemmal plaques of cytoskeletal laments on ultrastructural examination.6,9,29 These cells are important in normal and abnormal wound healing, and are pivotal elements in reactive proliferative conditions and within the stroma of certain neoplasms. Myobroblasts are recognized in a variety of pathologic conditions well characterized in humans, including hypertrophic scars, bromatoses, nodular fasciitis, and desmoplastic response to lung and mammary ductal carcinomas.23,26,30 Immunolabeling of tumors herein is consistent with those previous observations, and suggests a pervasive myobroblast-like phenotype within the histologic spectrum of feline vaccine-associated brosarcoma more than 60% of tumors studied contained cells labeled for -SMA. In some specimens, the majority of the tumor cells were immunoreactive for -SMA. Immunolabeled cells were clearly neoplastic and consisted of a differentiated cell population within the tumors (Fig. 5), or, in less frequent cases, formed a capsule surrounding the neoplasm adjacent to areas of intense peritumoral inammation (Fig. 6). Based on morphology and location, the cells along the periphery of the tumors (capsular pattern) seemed to be reactive rather than neoplastic. In one recent study in a rat colorectal tumor model, tumor-activated myobroblasts formed a capsule that enveloped tumor nodules, mechanically preventing penetration of T lymphocytes and macro-

Fig. 5. Vaccine-associated sarcoma; cat. Spindle neoplastic cell population (myobroblast-like cells) positive for smooth muscle actin (-SMA; black-stained cells) interspersed with nonreactive cells within the tumor. -SMA, avidin biotinperoxidase complex, Mayers hematoxylin counterstain. Bar 144 m. Fig. 6. Vaccine-associated sarcoma; cat. -smooth muscle actin (-SMA)positive cells (myobroblast-like) forming a capsule around tumor nodule (T tumor). -SMA, avidinbiotinperoxidase complex, Mayers hematoxylin counterstain. Bar 72 m.

Downloaded from vet.sagepub.com by guest on August 12, 2013

Vet Pathol 39:1, 2002

Morphology of Feline Vaccine-associated Sarcomas

39

phages into the tumor.18 If this mechanical action of myobroblasts is true for vaccine-associated sarcomas, it may account for the presence of abundant lymphocytes along the periphery of the tumors. T lymphocytes that would normally penetrate the tumor mass conceivably are blocked at the periphery of the nodule by the presence of the myobroblastic capsule. This might explain the high proportion of T cells in peritumoral follicular aggregates. The function and biological implications of myobroblasts in tumor growth are controversial. The proposal has been made that when present in the tumor stroma, myofribroblasts prevent invasion by stabilizing the extracellular matrix through the secretion of lysyl oxidase.18 Alternatively, adenocarcinomas transplanted into myobroblast-rich granulation tissue assumed a more invasive and aggressive phenotype.18 The origin of the myobroblast is controversial and any mesenchymal cell is a candidate. Whatever the cell of origin, differentiation into the myobroblastic phenotype is mainly modulated by cytokines. Myobroblastic differentiation is induced by transforming growth factor and granulocyte-macrophage colony-stimulating factor (GM-CSF), produced by activated macrophages. However, lymphocytes also play a key role in the activation of macrophages, and therefore, indirectly inuence the modulation of these cells.29 True tumors derived from myobroblasts are rare and not very well characterized in the cat.8 The myobroblastic differentiation of the vaccine sarcomas and the prominent associated inammation seem to be unique morphologic characteristics of this category of tumors that may be somehow related. Although we found no signicant association between the presence of myobroblast-like cells (-SMA-positive spindle cells) and inammation, further investigation of the cytokines that form the microenvironment of vaccine-reaction granulomas and vaccine sarcomas might elucidate some of the mechanisms involved. The therapeutic implications of GM-CSF, interferon-, or other immune regulatory compounds are currently speculative but could prove valuable for the treatment of vaccine sarcomas. In humans, myobroblasts are more common in tumorlike proliferations and low-grade soft-tissue sarcomas, and, therefore, the presence of myobroblasts has been associated with a favorable prognosis.31 This does not seem to be true in the case of feline vaccine-associated sarcomas, because these tumors are locally invasive. A close relationship between intratumoral microvascular density and tumor proliferation rate has been described recently.33 Mitotic activity quantitated within fast-growing areas along the periphery of a tumor (hot spots) also is known to be a more useful predictor of prognosis than mitotic activity quantitated from random tumor elds.1,14 Tumor cell proliferation depends,

in part, on adequate blood supply provided by neovascularization. Besides providing oxygen and nutrients, neoformed vessels inuence tumor growth and spread by means of several growth factors and other important substances, including collagenases, urokinases, and plaminogen activator, secreted by activated endothelial cells. These activated endothelial cells are believed to be located at newly formed capillaries within the growth fronts at the periphery of the tumor.1,33 High tumor microvessel density has been correlated with increased risk for metastasis and decreased survival time in human patients and with decreased postsurgical disease-free interval in dogs with mammary tumors.7,33 In the vaccine-associated sarcomas studied herein, although signicantly increased tumor microvessel density occurred at the tumor periphery compared to other tumor areas, no signicant difference was found between cellular proliferation rates when the two sites were compared. This could represent a biological characteristic of the feline vaccinesarcomas and would be a possible explanation to the commonly observed central areas of cavitation within the larger masses.5 If the proliferation rate of the tumor is equivalent throughout the mass but the vascularity is higher along the peripheral areas, the tumor cells located within the central areas may eventually outgrow the vascular supply, undergoing necrosis and subsequently forming areas of cavitation. Lung carcinomas are another example of tumors that commonly present a similar central cavitary portion secondary to necrosis.24 However, the cavities lined by granulation tissue may form secondary to a vaccine-induced necrotizing reaction with seroma formation from which the tumor subsequently arises. In summary, in the 44 brosarcomas examined, wide variations occurred in cellular differentiation, mitotic index, and necrosis that allowed separation of the tumors into three histologic grades. Independent of the grade, the brosarcomas shared several morphologic characteristics, including the presence of peritumoral T cellpredominant lymphoid inammation, accentuated peripheral vascularity, variably distributed myobroblast-like cells, and neoplastic multinucleated giant cells. Macrophages containing presumed adjuvant material were not always seen in the tumors. Central cavitations, possibly resulting from previous vaccineinduced necrotizing panniculitis, were often observed in gross specimens. The neoplastic multinucleated giant cells only occurred in high histologic grade tumors and may indicate a more poorly differentiated tumor phenotype. Whether the presence of these giant cells, or other morphologic attributes of feline vaccine-associated brosarcoma, may provide prognostic information requires further investigation. Fibrosarcoma was the most frequent histologic type; however, be-

Downloaded from vet.sagepub.com by guest on August 12, 2013

40

Couto, Griffey, Duarte, and Madewell

Vet Pathol 39:1, 2002

cause of the marked cellular pleomorphism within each tumor, we agree with the current and more accurate classication of these tumors as simply vaccineassociated sarcomas. Acknowledgements
We wish to thank Dr. Alexandre Basso for assistance with initial data collection, Diane Naydan for immunohistochemistry, Dr. Peter F. Moore for valuable help with photomicrography, and Dr. Frank Verstraete for the image analysis equipment. This study was supported by the Dubee Fund, the Sacramento County Veterinary Medical Association, and the Center for Companion Animal Health, School of Veterinary Medicine, University of California.

15 16

17

References
1 Belie n JAM, Van Diest PJ, Baak JPA: Relationships between vascularization and proliferation in invasive breast cancer. J Pathol 189:309318, 1999 2 Bostock DE, Dye MT: Prognosis after surgical excision of canine brous connective tissue sarcomas. Vet Pathol 17:581588, 1980 3 Coindre JM, Nguyen BB, Bonichon F, de Mascarel I, Trojani M: Histopathologic grading in spindle cell soft tissue sarcomas. Cancer 61:23052309, 1988 4 Cyster JG: Chemokines and cell migration in secondary lymphoid organs. Science 286:20982102, 1999 5 Doddy FD, Glickman LT, Glickman NW, Janovitz EB: Feline brosarcomas at vaccination sites and non-vaccination sites. J Comp Pathol 114:165174., 1996 6 Dubielzig RR, Hawkins KL, Miller PE: Myobroblastic sarcoma originating at the site of rabies vaccination in a cat. J Vet Diagn Invest 5:637638, 1993 7 Griffey SM, Verstraete FJM, Kraegel SA, Madewell BR: Computer assisted image analysis of intratumoral vessel density in canine mammary tumors. Am J Vet Res 59: 12381242, 1998 8 Hayden DW, Ghobrial HK, Johnson KH, Buoen LC: Feline mammary sarcoma composed of cells resembling myobroblasts. Vet Pathol 23:118124, 1986 9 Hendrick MJ, Brooks JJ: Postvaccinal sarcomas in the cat: histology and immunohistochemistry. Vet Pathol 31: 126129, 1994 10 Hendrick MJ, Goldschmidt MH: Do injection site reactions induce brosarcomas in cats? J Am Vet Med Assoc 199:968, 1991 11 Hendrick MJ, Goldschmidt MH, Shofer FS, Wang Y-Y, Somlyo AP: Postvaccinal sarcomas in the cat: epidemiology and electron probe microanalytical identication of aluminum. Cancer Res 52:53915394, 1992 12 Hendrick MJ, Kass PH, McGill LD: Postvaccinal sarcomas in cats. J Natl Cancer Inst 86:341343, 1994 13 Hendrick MJ, Shofer FS, Goldschmidt MH, Haviland JC, Schelling SH, Engler SJ, Gliatto JM: Comparison of brosarcomas that developed at vaccination sites and at nonvaccination sites in cats: 239 cases (19911992). J Am Vet Med Assoc 205:14251429, 1994 14 Jannink I, van Diest PJ, Baak JP: Comparison of the prognostic value of four methods to assess mitotic activ-

18

19 20

21

22

23 24 25 26 27 28 29

30

ity in 186 invasive breast cancer patients: classical and random mitotic activity assessments with correction for volume percentage of epithelium. Hum Pathol 26:1086 1092, 1995 Jo sten M, Rudolph R: Methods for the differentiation of giant cells in canine and feline neoplasias in parafn sections. J Vet Med Sci 44:159166, 1997 Kandel RA, Bell RS, Wunder JS, OSullivan B, Catton CN, White LM, Davis AM: Comparison between a 2and 3-grade system in predicting metastatic-free survival in extremity soft tissue sarcoma. J Surg Oncol 79:7782, 1999 Kass PH, Barnes WG, Spangler WL, Chomel BB, Culbertson MR: Epidemiologic evidence for a causal relation between vaccination and brosarcoma tumorigenesis in cats. J Am Vet Med Assoc 203:396405, 1993 Lieubeau B, Heymann MF, Henry F, Barbieux I, Meah K, Gregoire M: Immunomodulatory effects of tumor-associated broblasts in colorectal tumor development. Int J Cancer 81:629636, 1999 Macy DW, Bergman PJ: Vaccine-associated sarcomas in cats. Feline Pract 23:2427, 1995 Macy DW, Hendrick MJ: The potential role of inammation in the development of postvaccinal sarcomas in cats. Vet Clin North Am Small Anim Pract 26:103109, 1996 Madewell BR, Griffey SM, Mc Entee MC, Leppert VJ, Munn RJ: Feline vaccine-associated brosarcomas: an ultrastuctural study of 20 cases (19961999). Vet Pathol 38:196202, 2001 Mandard AM, Petiot JF, Marnay J, Mandard JC, Chasle J, de Ranieri E, Dupin P, Herlin P, de Ranieri J, Tanguy A, Boulier N, Abbatucci JS: Prognostic factors in soft tissue sarcomas. A multivariate analysis of 109 cases. Cancer 63:14371451, 1989 Mentzel T, Fletcher CDM: The emerging role of myobroblasts in soft tissue neoplasia. Am J Clin Pathol 107: 25, 1997 Moulton JE: Tumors in Domestic Animals, 3rd ed. pp. 323324. University of California Press, Berkeley, CA, 1990 Powers BE, Hoppes PJ, Ehrhart EJ: Tumor diagnosis, grading and staging. Semin Vet Med Surg Small Animal 10:158167, 1995 Roche WR: Myobroblasts. J Pathol 161:281282, 1990 Rosai J: Liver cell carcinoma with osteoclast-like giant cells: nonepitheliogenic giant cells in diverse malignancies. Hepatology 12:782783, 1990 Schultze AE, Frank LA, Hahn KA: Repeated physical and cytologic characterizations of subcutaneous postvaccinal reactions in cats. Am J Vet Res 58:719724, 1997 Schu rch W, Seemayer TA, Gabbiani G: Myobroblast. In: Histology for Pathologists, ed. Sternberg SS, 2nd ed., pp. 129165. Lippincott-Raven Publishers, Philadelphia, PA, 1997 Skalli O, Schu rch W, Seemayer T, Lagace R, Montandon D, Pittet B, Gabbiani G: Myobroblasts from diverse pathologic settings are heterogeneous in their content of actin isoforms and intermediate lament proteins. Lab Invest 60:275285, 1989

Downloaded from vet.sagepub.com by guest on August 12, 2013

Vet Pathol 39:1, 2002

Morphology of Feline Vaccine-associated Sarcomas

41

31 Stiller D, Katenkamp D: Cellular features in desmoid bromatosis and well-differentiated brosarcomas: an electron microscopic study. Virchows Arch A Pathol Anat Histol 369:155164., 1975 32 Tarlington D: Germinal centers: form and function. Curr Opin Immunol 10:245251, 1998

33 Weidner N: Tumour vascularity and proliferation: clear evidence of a close relationship. J Pathol 189:297299, 1999 34 Willett CG, Schiller AL, Suit HD, Mankin HJ, Rosenberg A: The histologic response of soft tissue sarcoma to radiation therapy. Cancer 60:15001504, 1987

Request reprints from Dr. S. S. Couto, Anatomic Pathology Service, Veterinary Medical Teaching Hospital, University of CaliforniaDavis, 1 Garrod Drive, Davis, CA 95616 (USA). E-mail: sscouto@ucdavis.edu.

Downloaded from vet.sagepub.com by guest on August 12, 2013